New pill targets hard-to-treat blood cancers in early trial
NCT ID NCT05549661
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new oral drug called onvansertib for people with chronic myelomonocytic leukemia (CMML) or related blood cancers that have returned or stopped responding to standard treatments. The drug works by blocking a protein that helps cancer cells grow. The main goals are to find the safest dose and see if it can shrink or control the cancer. About 25 adults will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for rare blood cancers: interferon trial launches
- Could detoxing metals boost chemo for leukemia?
- New combo attack on stubborn leukemia: chemo then transplant
- New drug combo aims to shrink Hard-to-Treat blood cancers
- New hope for tough blood cancers: first human trial launches
- New hope for blood cancer patients: canakinumab trial targets Low-Risk MDS and CMML